PREVENTION LAB – HIV & STI: Change the course. PREVENT!
PREVENTION LAB – HIV & STI: Change the course. PREVENT!
Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy.
Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy.
Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy.
Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy.
Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy.
Razionale Scientifico | PREVENTION LAB – HIV & STI: Change the...
Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Epidemiological data from recent years show a stable incidence of new diagnoses, particularly among specific key populations, highlighting limitations in the implementation, access, and adherence to currently available prevention tools. These challenges are compounded by social and structural determinants, such as stigma, discrimination, and marginalization, which continue to hinder the effectiveness of prevention programs.
The National Conference represents a high-level scientific forum aimed at critically and multidisciplinarily analyzing HIV and related infection prevention strategies, integrating epidemiological evidence, public health models, therapeutic innovation, and person-centered approaches. The objective is to promote an up-to-date vision of combination prevention, aligned with international recommendations and the needs of the national context, with the goal of fostering continuous professional development among healthcare workers, encouraging the adoption of evidence-based preventive strategies, and contributing to the development of more effective, equitable, and sustainable HIV prevention models.
The program also addresses the role of social determinants of health, with particular attention to the impact of stigma and discrimination on access to prevention services. In this context, the identification and characterization of populations at higher risk represent a crucial step in the development of targeted and effective interventions.
The use of risk assessment models and outcome indicators can enable the measurement of the impact of preventive strategies and guide evidence-based health policies. In parallel, updates on HIV testing strategies and partner notification emphasize the importance of early diagnosis as a cornerstone of prevention.
A central area of scientific discussion is dedicated to pre-exposure prophylaxis (PrEP), recognized as one of the most effective tools for HIV prevention. The program examines the current state of PrEP implementation, with particular attention to delivery models, territorial dissemination, and challenges related to access, adherence, and retention. It also explores the role of community engagement and peer educators in improving the effectiveness of preventive interventions and reducing inequalities in access, particularly among populations such as women, young people, migrants, and transgender individuals.
The forward-looking perspective is further expanded through the analysis of long-acting PrEP formulations, from their biological foundations to clinical trial results and early implementation experiences. These new approaches represent a significant evolution in pharmacological prevention, with the potential to overcome some of the limitations of oral PrEP and to better address the needs of currently underserved populations.
Another key pillar of the program is Treatment as Prevention (TasP), discussed both in the context of rapid initiation of antiretroviral therapy in newly diagnosed individuals and in strategies for re-engagement in care and management of adherence challenges to antiretroviral therapy. The evidence supporting virological suppression as a prevention tool, in accordance with the U=U (Undetectable = Untransmittable) concept, is applied to complex clinical scenarios, including those characterized by high clinical and social vulnerability.
Finally, the program integrates HIV prevention with vaccination strategies in high-risk populations and in people with HIV, examining the role of anti-HPV, anti-pneumococcal-, and anti-Herpes Zoster vaccination in preventing comorbidities and long-term complications. This approach reflects a modern and integrated vision of prevention, aimed not only at reducing HIV transmission but also at improving overall health and quality of life.
The Conference is intended for Physicians specialized in Infectious Diseases, Hygiene and Public Health, Internal Medicine, Microbiology and Virology, Epidemiology.
Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Epidemiological data from recent years show a stable incidence of new diagnoses, particularly among specific key populations, highlighting limitations in the implementation, access, and adherence to currently available prevention tools. These challenges are compounded by social and structural determinants, such as stigma, discrimination, and marginalization, which continue to hinder the effectiveness of prevention programs.
The National Conference represents a high-level scientific forum aimed at critically and multidisciplinarily analyzing HIV and related infection prevention strategies, integrating epidemiological evidence, public health models, therapeutic innovation, and person-centered approaches. The objective is to promote an up-to-date vision of combination prevention, aligned with international recommendations and the needs of the national context, with the goal of fostering continuous professional development among healthcare workers, encouraging the adoption of evidence-based preventive strategies, and contributing to the development of more effective, equitable, and sustainable HIV prevention models.
The program also addresses the role of social determinants of health, with particular attention to the impact of stigma and discrimination on access to prevention services. In this context, the identification and characterization of populations at higher risk represent a crucial step in the development of targeted and effective interventions.
The use of risk assessment models and outcome indicators can enable the measurement of the impact of preventive strategies and guide evidence-based health policies. In parallel, updates on HIV testing strategies and partner notification emphasize the importance of early diagnosis as a cornerstone of prevention.
A central area of scientific discussion is dedicated to pre-exposure prophylaxis (PrEP), recognized as one of the most effective tools for HIV prevention. The program examines the current state of PrEP implementation, with particular attention to delivery models, territorial dissemination, and challenges related to access, adherence, and retention. It also explores the role of community engagement and peer educators in improving the effectiveness of preventive interventions and reducing inequalities in access, particularly among populations such as women, young people, migrants, and transgender individuals.
The forward-looking perspective is further expanded through the analysis of long-acting PrEP formulations, from their biological foundations to clinical trial results and early implementation experiences. These new approaches represent a significant evolution in pharmacological prevention, with the potential to overcome some of the limitations of oral PrEP and to better address the needs of currently underserved populations.
Another key pillar of the program is Treatment as Prevention (TasP), discussed both in the context of rapid initiation of antiretroviral therapy in newly diagnosed individuals and in strategies for re-engagement in care and management of adherence challenges to antiretroviral therapy. The evidence supporting virological suppression as a prevention tool, in accordance with the U=U (Undetectable = Untransmittable) concept, is applied to complex clinical scenarios, including those characterized by high clinical and social vulnerability.
Finally, the program integrates HIV prevention with vaccination strategies in high-risk populations and in people with HIV, examining the role of anti-HPV, anti-pneumococcal-, and anti-Herpes Zoster vaccination in preventing comorbidities and long-term complications. This approach reflects a modern and integrated vision of prevention, aimed not only at reducing HIV transmission but also at improving overall health and quality of life.
The Conference is intended for Physicians specialized in Infectious Diseases, Hygiene and Public Health, Internal Medicine, Microbiology and Virology, Epidemiology.
Despite the significant progress achieved in the prevention and treatment of HIV infection, viral transmission remains a public health challenge in Europe and in Italy. Epidemiological data from recent years show a stable incidence of new diagnoses, particularly among specific key populations, highlighting limitations in the implementation, access, and adherence to currently available prevention tools. These challenges are compounded by social and structural determinants, such as stigma, discrimination, and marginalization, which continue to hinder the effectiveness of prevention programs.
The National Conference represents a high-level scientific forum aimed at critically and multidisciplinarily analyzing HIV and related infection prevention strategies, integrating epidemiological evidence, public health models, therapeutic innovation, and person-centered approaches. The objective is to promote an up-to-date vision of combination prevention, aligned with international recommendations and the needs of the national context, with the goal of fostering continuous professional development among healthcare workers, encouraging the adoption of evidence-based preventive strategies, and contributing to the development of more effective, equitable, and sustainable HIV prevention models.
The program also addresses the role of social determinants of health, with particular attention to the impact of stigma and discrimination on access to prevention services. In this context, the identification and characterization of populations at higher risk represent a crucial step in the development of targeted and effective interventions.
The use of risk assessment models and outcome indicators can enable the measurement of the impact of preventive strategies and guide evidence-based health policies. In parallel, updates on HIV testing strategies and partner notification emphasize the importance of early diagnosis as a cornerstone of prevention.
A central area of scientific discussion is dedicated to pre-exposure prophylaxis (PrEP), recognized as one of the most effective tools for HIV prevention. The program examines the current state of PrEP implementation, with particular attention to delivery models, territorial dissemination, and challenges related to access, adherence, and retention. It also explores the role of community engagement and peer educators in improving the effectiveness of preventive interventions and reducing inequalities in access, particularly among populations such as women, young people, migrants, and transgender individuals.
The forward-looking perspective is further expanded through the analysis of long-acting PrEP formulations, from their biological foundations to clinical trial results and early implementation experiences. These new approaches represent a significant evolution in pharmacological prevention, with the potential to overcome some of the limitations of oral PrEP and to better address the needs of currently underserved populations.
Another key pillar of the program is Treatment as Prevention (TasP), discussed both in the context of rapid initiation of antiretroviral therapy in newly diagnosed individuals and in strategies for re-engagement in care and management of adherence challenges to antiretroviral therapy. The evidence supporting virological suppression as a prevention tool, in accordance with the U=U (Undetectable = Untransmittable) concept, is applied to complex clinical scenarios, including those characterized by high clinical and social vulnerability.
Finally, the program integrates HIV prevention with vaccination strategies in high-risk populations and in people with HIV, examining the role of anti-HPV, anti-pneumococcal-, and anti-Herpes Zoster vaccination in preventing comorbidities and long-term complications. This approach reflects a modern and integrated vision of prevention, aimed not only at reducing HIV transmission but also at improving overall health and quality of life.
The Conference is intended for Physicians specialized in Infectious Diseases, Hygiene and Public Health, Internal Medicine, Microbiology and Virology, Epidemiology.
